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ABSTRACT 
Background 
Pre-eclampsia can result in abnormal platelet function and count.  Due to lack of resources 
and the subsequent over burden of specimens sent to our National Health Laboratory Services 
(NHLS), these results may not be obtained on time.  Obstetricians and anaesthetists therefore 
make assumptions about platelet count in pre-eclamptic women – a common assumption is 
that a low platelet count will drop further as long as the woman remains pregnant. This may 
lead to unnecessary clinical and anaesthetist decisions in patient management.   
 
Objective  
This dissertation questions the predictability, at least while pregnancy continues, of platelet 
count trends in women who have pre-eclampsia with thrombocytopaenia, and also aims to 
identify factors associated with trends in platelet count in these women. 
 
Methods  
This study had a cohort design with data collected prospectively.  Women who had 
thrombocytopenia as a complication of pre-eclampsia, with follow-up results while still 
pregnant, were included.  Women were recruited at all three academic hospitals attached to 
the University of the Witwatersrand .  No interventions were done, and all platelet count 
results used were from blood tests done as part of the management of each patient.  Follow-
up platelet counts were compared with initial platelet counts and observed for changes, using 
statistical tests for paired data, guided by a significance level of p<0.05. 
vii 
 
Results 
Thirty two women were entered into the study.  For all the women, the median first platelet 
count on admission into the study was 112x10
9
/L and the median follow-up platelet count 
was 99x10
9
L, with no significant difference (Wilcoxon signed rank test for paired data, 
p=0.78).  However, in the 12 women with raised aspartate aminotransferase (AST) levels on 
admission (AST≥40 U/L), the platelet count decreased by a mean of 19.7 x109/L (Student’s t-
test for paired data; p<0.01). No other measured risk factors were associated with decreases 
in platelet count. 
 
Conclusion   
The platelet count in women with pre-eclampsia who have thrombocytopenia can be 
predicted only in the groups with raised AST or HELLP syndrome (p < 0.01). 
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INTRODUCTION 
 
Pre-eclampsia, commonly defined as new-onset pregnancy induced hypertension with 
proteinuria that develops after 20 weeks gestation, can result in abnormal platelet function 
and count.
1
  Expectantly managed pre-eclampsia generally deteriorates and platelet counts 
may fall with time.  However, frequent serial testing of pre-eclamptic women may not be 
feasible due to lack of resources and the subsequent burden and backlog of specimens sent to 
our National Health Laboratory Services (NHLS).  We have observed that obstetricians and 
anaesthetists therefore make assumptions about thrombocytopenia and platelet count decline 
in pre-eclamptic women.  A common assumption is that a low platelet count will drop further 
as long as the pre-eclamptic woman remains pregnant. This leads, for example, to the use of 
pre-operative prophylactic platelet transfusions for pre-eclamptic women who do not have 
severe thrombocytopaenia. This dissertation questions the predictability of platelet count 
trends in women who have pre-eclampsia with thrombocytopaenia.     
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1. LITERATURE REVIEW 
 
1.1 Epidemiology 
In 2010 the worldwide incidence of pre-eclampsia in pregnancy was between 2-8%, 
occurring more commonly in low income areas.
2 
 The incidence appears to be on the increase 
in developed countries too.
2,3
  Figures differ according to geographic location as pre-
eclampsia incidence may be influenced by environmental, socio- economic and genetic 
factors.
2,3 
 
In the 2011-2013 “Saving Mothers Report for South Africa”, death from hypertension and its 
associated complications were recorded as the third highest cause of maternal mortality 
(14.8%) after non pregnancy related infections, and haemorrhage.
4
  Mortality from 
hypertensive disorders in pregnancy occurs most commonly due to neurological 
complications of eclampsia and cerebral haemorrhage.
4
  What was concerning in the report 
was that majority of the deaths were avoidable and were as a result of failed recognition of 
diagnosis and severity, lack of resources and delayed intervention.
4
  Reduction in maternal 
death is one of the key goals in the Millennium Development Goals, and can therefore be 
attained with improved training of health professionals and provision of resources to health 
care facilities and to the community at large.
5
  
 
Severe thrombocytopenia and HELLP syndrome are well known complications associated 
with pre-eclampsia, complicating 10% of affected pregnancies.
3,6
  Severe complications 
3 
 
occur more frequently in early-onset pre-eclampsia (onset before 34 weeks) and in patients 
with previous underlying cardiovascular and autoimmune diseases.
6 
 
Patients at risk for pre-eclampsia 
Risk factors include age over 40 years, African descent, low socio-economic status, 
nulliparity, previous pre-eclampsia, an interval of more than 10 years between antecedent and 
current pregnancy, obesity, underlying medical conditions such as diabetes, kidney disease 
and chronic hypertension, and the presence of antiphospholipid antibodies.
7
 
 
1.2 Pre-eclampsia 
Definitions and classification 
The definitions and classifications of pre-eclampsia and its severity differ between 
professional groups such as the Society of Obstetrics Medicine of Australia and New Zealand 
(SOMANZ), the Royal College of Obstetrics and Gynaecology (RCOG), the American 
College of Obstetricians and Gynecologists (ACOG), the Society of Obstetricians and 
Gynaecologists of Canada (SOGC) and the International Society for the Study of 
Hypertension in Pregnancy (ISSHP).
8,9,10,11,12
 
 
The SOMANZ classification uses the definition of pre-eclampsia as the onset of hypertension 
typically after 20 weeks, but there are cases that may develop before 20 weeks.  Hypertension 
must be associated with features of end organ damage in relation to the renal, haematological, 
liver, neurological, respiratory, cardiovascular and uteroplacental systems.
8
  The 
4 
 
classification does not include proteinuria as mandatory 
 
and uses a limit of systolic blood 
pressure ≥170 mmHg.8 
 
The RCOG unlike the other institutions does not include uteroplacental insufficiency in their 
definition.
9
  The ACOG necessitates the definition of pre-eclampsia to include proteinuria 
and use a lower cut off systolic blood pressure (≥160 mmHg) compared to the SOMANZ 
classification.
11
 The former makes a clear distinction between mild and severe pre-
eclampsia.
10
  The SOGC published an article in 2014 regarding newest evidence surrounding 
pre-eclampsia and have recommended complete removal of definitions of mild and moderate 
pre-eclampsia.
11  
The ISSHP aimed to clarify the uncertainties involving the definition and 
classification of pre-eclampsia by the various societies.
12 
 One of the questions raised was 
whether the presence of proteinuria was mandatory for the diagnosis, due to the high false 
positive readings associated with urine dipsticks, as well as the expense and time taken to 
collect a 24 hour urine sample.
12 
 The ISSHP agreed that in clinical practice it is not 
mandatory to include proteinuria, but in the academic setting where research will occur, 
inclusion of proteinuria in the diagnosis of pre-eclampsia would make selection more 
uniform.
12 
 
The Department of Obstetrics and Gynaecology affiliated to the University of the 
Witwatersrand (Wits) generally favours the SOMANZ classification of pre-eclampsia, with 
aspects similar to those of the ACOG and ISSHPP definitions.
13
  The Wits definition, which 
is used in this dissertation includes
 
the 160 mmHg systolic blood pressure cut off for severe 
hypertension and the inclusion of proteinuria in the definition, as well as the distinction of 
mild and moderate pre-eclampsia.
13 
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1.3 Pre-eclampsia pathogenesis 
Pre-eclampsia is described as the “disease of theories” because although research has been 
conducted for many years it still remains poorly understood and unpredictable, thus 
management and classification of the condition is still under debate.
14
  The disease process, 
initiated within the placenta and the vascular endothelium, starts early in pregnancy, many 
weeks before manifestation of clinical disease.
14,15
  The common theory that pre-eclampsia is 
primarily a placental function disorder is further reinforced by cases with molar and 
anembryonic pregnancies which develop pre-eclampsia that resolves only after the pregnancy 
has been terminated.
15
 
 
1.3.1 Early and late onset pre-eclampsia 
The pathophysiologies of early and late onset pre-eclampsia are believed to differ.
15
  Early 
onset disease, which is clinical onset at less than 34 weeks gestation, is believed to occur as a 
result of abnormal adaptation and functioning of the placenta, immunological factors and 
abnormal endometrial preparation.
15
  This results in impaired fetal growth.  
Haemodynamically there is typically a low cardiac output, increased peripheral resistance and 
small left ventricular size.
17
  Von Dadelszen et al. refer to it as “placental pre-eclampsia.”11,15  
Late onset disease, the clinical onset of pre-eclampsia after 34 weeks, appears to be more 
influenced by the underlying maternal condition of chronic hypertension or obesity as well as 
endothelial dysfunction.
11,16
  This causes changes in vessels of the decidua, resulting in poor 
adaption of the spiral arterioles to the pregnancy between 10-15 weeks as well as abnormal 
cardiovascular response to normal pregnancy.
15,16
  Haemodynamic studies reveal reduced 
peripheral resistance, increased cardiac output and left ventricular enlargement.
17
  Von 
6 
 
Dadelszen et al. refer to this as “maternal pre-eclampsia”.15  In some patients the early and 
late onset disease processes may be combined.
12,17   
 
 
 
1.3.2 Abnormal placentation 
The placental insult begins as early as day 11 after fertilization with abnormal formation of 
the placenta.
18   
In normal placental development the first phase of invasion occurs by week 
12 where the cytotrophoblast invades the spiral arterioles within the decidua.  By week 16 the 
second invasion occurs where the trophoblast invades even deeper into the myometrium and 
radial arteries.
18
 
   
 
 
Abnormal placental development is believed to be influenced by multiple predisposing 
factors which include genetics, abnormally functioning natural killer cells, human leukocyte 
antigen (HLA) types C, D, E (which are the regulators controlling the remodelling of vessels 
to adapt to pregnancy), reduced levels of CD4+ T regulatory cells and increased levels of T 
helper 17 (found to be increased in some autoimmune conditions).
17
  Decreased release of 
Notch ligand JAG1, has also been found in placental tissue (notch signals regulate the 
formation of blood vessels).
17
  Abnormal placental formation results in narrow and thick 
walled spiral arterioles, instead of the large-calibre, virtually amuscular vessels seen in 
normal pregnancy.
19
  The placenta then becomes hypoperfused, with the hypoxic stress 
adding to local damage. 
 
7 
 
1.3.3 Endothelial dysfunction
 
Fragments of placental debris may then be released into the maternal blood stream. Examples 
of the fragments include activated neutrophils, activated monocytes, lipid peroxidase and 
oxidised syncytiotrophoblast.
19
 
 
The fragments cause an immune response and result in an exaggerated systemic 
inflammatory response.
17
  The maternal vascular endothelium is chiefly affected, with 
damage especially to vessels in the kidneys, brain and liver, and an abnormal increase in 
endothelial activation.
17
  In pre-eclampsia the balance of maintaining vascular tone is skewed, 
favouring the release of vasoconstrictive substances and increased vascular tone.
17
  Factors 
that signify damage to the endothelium can be found in the blood stream several weeks 
before the clinical manifestation of pre-eclampsia.  These include Fms-like tyrosine kinase 1 
and soluble endoglin.
17
  Fms-like tyrosine kinase 1 decreases Vascular endothelial growth 
factor  and Placental growth factor  levels (which are factors that maintain endothelial cells)  
and soluble endoglin inhibits binding of  transforming growth factor 1 to the endothelial , 
impairing the action of vasodilator and antiplatelet aggregator nitic oxide (NO).
17
   
 
1.3.4 Eicosanoid imbalance 
Maternal vascular tone is maintained by endothelial production of vasoconstrictors and 
vasodilators. Walsh states that studies showing decreased prostaglandin E and prostacyclin 
combined with increased prostaglandin F2 alpha and thromboxane production have shown 
that eicosanoids play a role in pre-eclampsia.
20 
 This imbalance is triggered by oxidised 
fragments released by the placenta that activate cyclooxygenase enzymes to produce 
8 
 
thromboxane and inhibit the actions of prostacyclin synthase thus decreasing  prostacyclin 
synthesis.
20
  Walsh further suggests that decreased prostacyclin correlates with mild pre-
eclampsia whereas increased thromboxane is associated with severe pre-eclampsia.
20  
The 
prostaglandin imbalance contributes to platelet aggregation, a critical component of the 
pathophysiology of pre-eclampsia. 
 
1.4 Platelet physiology 
1.4.1 Structure 
Platelets are miniscule, anucleated blood cells that consist of cytoplasmic organelles, a 
cytoskeleton and granules.
21 
 They generally have a flat surface and are irregular in shape, 
which allows for haemostasis.  The shape of platelets is dynamic and changes depending on 
the level of activation, where the activated platelet has an irregular branch-like shape and the 
resting platelet has a smoother surface.
22
  The size also differs depending on the maturity of 
the cell, where the more immature the platelet, the larger the size.
22,23 
 
Over 200 billion platelets are produced within the cytoplasm of a mature megakaryocyte 
every day.
23
  They are the second most common blood constituent after red blood cells.
23
  
Their life span ranges from 7 to 10 days and the normal platelet count is between 150 and 
400x10
9
/L.
23 
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1.4.2 Platelet production and life cycle
 
Megakaryocytes are large cells found within the bone marrow, and a small percentage are 
also found peripherally in the spleen, blood and respiratory system.
23 
 Platelets originate from 
a single pluripotent haematopoietic stem cell which produces an uncommitted common 
myeloid progenitor cell.
24
 This common myeloid progenitor cell has the potential to become 
any component in the haematological system, such as red and white blood cells as well as 
platelets.
23,24   
Therefore, under the influence of thrombopoeitin, the common myeloid 
progenitor cell produces megakaryocyte progenitor cells, which can then form immature 
megakaryocytes, and finally after various structural and biochemical changes, the mature 
megakaryocyte.
23,24
  
 
 
These various structural and biochemical changes are divided into two phases that result in 
platelet formation, in which thrombopoietin is the main initiating and controlling factor.
23 
Phase 1 occurs under the influence of growth factors that allow the nucleus and the cytoplasm 
of the megakaryocyte to enlarge, and at the same time cytoskeletal proteins, alpha (CD62P) 
and dense (CD63) platelet-specific granules and membrane accumulate within the platelet 
and aid in development.
22 
 Phase 2 is where the cytoplasm matures to form proplatelets, 
which branch outwards to become preplatelets and then finally mature.
23 
 The products that 
are released from the tips of these branches are platelets, and the remainder of the cell 
degenerates.
23 
 
 
 
10 
 
1.4.3 Platelet function  
The main role of platelets is protective, as the first line in maintaining primary and secondary 
haemostasis.
22 
 In response to endothelial damage, irrespective of the mechanism of injury, 
platelets are programmed to aggregate rapidly at the site of injury and start formation of the 
haemostatic fibrin/ platelet plug.
22   
The process is initiated when the damaged endothelium 
releases Von Willebrand Factor (VWF), fibronectin and laminin, causing the platelets to bind 
either directly to the subendothelial matrix proteins or indirectly by binding to VWF.
22
  The 
latter mechanism slows down the movement of the platelet causing it to “roll” along the 
vessel wall towards the site of injury.
22,24 
 Binding is further reinforced when the collagen 
binds to the platelet surface receptor, resulting in platelet activation.
22 
 In the inactive form, 
platelets have glycoproteins on the membrane surface, e.g. fibrinogen receptor and CD62P 
and CD63.
24 
 When activated, the platelet increases the expression of membrane 
glycoproteins and increases the release of granules. There is also an associated change in 
shape, causing the platelet to develop branch-like outgrowths called filopodia and 
lamelipodia.
24
  The process is further accompanied by increased surface expression of 
phosphatidylserine and platelet degranulation, resulting in the activated platelet.
24 
 Activation 
causes release of thromboxane, ADP, serotonin and VWF with further platelet recruitment, 
activation, aggregation, spreading, release reactions, and induction of pro-coagulant 
activity.
23,24 
 This exposes phospholipid binding sites, eventually resulting in the release of 
thrombin and formation of the haemostatic plug.
23,24 
 The physiological role of platelets is not 
limited to haemostasis. Other functions include roles in inflammation, vasoconstriction, and 
wound healing.
22
 
 
 
11 
 
1.5 Measurement of the platelet count 
Platelet count, in the context of pre-eclampsia and its complications, is used to determine the 
severity of disease, and helps the clinician decide when to expedite delivery.  It is also used to 
determine the mode of anaesthesia as well as whether a platelet transfusion is required. 
 
Measuring the platelet count using full blood count technology is only one example of how 
platelet function is assessed, acting as a screening tool and raising red flags if an abnormal 
count is reported.
22
  However, the count itself cannot establish the cause of 
thrombocytopaenia, and further functional tests need to be conducted.
26 
 
 
Blood for full blood count is taken in an ethylene diamine tetra-acetic acid (EDTA) tube that 
contains an anticoagulant (usually buffered sodium citrate).
27
  Correct technique is required 
to ensure that a good sample is taken and accurately measured. This includes use of a 
tourniquet applying light circumferential pressure to the arm, a 21 gauge needle or larger, and 
easy aspiration of blood to a specimen volume of at least 2 mL for accurate analysis.
27  
A 
little-known point is that the initial 2 mL aspirated should be discarded.  This diminishes the 
chances of artefacts and platelet clumping as a result of the blood clotting, which would give 
a falsely low value of platelets.
27   
 
 
Where a full blood count shows a very low platelet count or abnormal platelet morphology, 
manually evaluating and counting of platelets under the microscope can still be used.  Both of 
these factors can be missed or falsely identified with the automated machine.
27
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1.6 Thrombocytopenia in pregnancy  
Thrombocytopenia, defined as a platelet count <150 x10
9 
/L, affects 7-10% of pregnancies.
28
   
1.6.1  Causes are as follows:
21,29 
1. Decreased production in the bone marrow 
 
 Haematological malignancies (e.g. leukaemia) 
 Aplastic anaemia 
 Myelodysplasia 
 Bone marrow infiltration from metastasis 
 HIV infection 
 Drugs 
 Radiation 
 Vitamin D deficiencies  
 Hereditary thrombocytopenia 
 
2. Increased destruction. 
Immune-related peripheral destruction 
 ITP (immune thrombocytopenic purpura) 
 HIT (heparin induced thrombocytopenia) 
 Drug induced 
 HIV infection 
 Post-transfusion purpura 
 Connective tissue diseases (systemic lupus erythematosus,  
13 
 
     antiphospholipid syndrome, vasculitis) 
 Pre-eclampsia and HELLP syndrome 
 Acute fatty liver of pregnancy 
 
Non-immune related peripheral destruction. 
 Disseminated intravascular coagulopathy (DIC) 
 Sepsis 
 Cardiac valves 
 Thrombotic thrombocytopenia purpura-haemolytic uraemic syndrome 
 Kasabach Merrit syndrome 
 Haemodialysis 
 Endocarditis 
 
Splenic Sequestration 
 Hypersplenism 
 
All of the above causes, other than pre-eclampsia, HELLP syndrome and acute fatty liver, are 
not specific to pregnancy.  The causes in pregnancy are predominantly secondary to increased 
destruction.  The focus of the rest of this section will be on the differential diagnosis of 
thrombocytopenia in pregnancy.
29   
 
 
 
14 
 
1.6.2 Gestational thrombocytopenia
 
Gestational thrombocytopenia is the most frequent cause of low platelets that occur after 20 
weeks gestation.
28
  It typically presents in the third trimester, resulting in a mild form of 
thrombocytopenia (no clear numerical value) and requires no treatment.
28
  The platelet count 
returns to a normal value within 12 weeks after delivery and has no adverse effect on mother 
or baby.
28 
 Gestational thrombocytopaenia is a diagnosis of exclusion that can mimic early 
features of HELLP syndrome, especially when the blood pressure is not yet elevated. 
Functionally, it has no clinical significance.
21 
 
1.6.3 Thrombotic thrombocytopenic purpura  
Thrombotic thrombocytopenic purpura (TTP) is described as micrangiopathic haemolytic 
anaemia together with fever, thrombocytopenia and neurological symptoms (headache, 
seizures, altered levels of consciousness).
21,30 
 It should always be in the differential diagnosis 
of thrombocytopenia in pregnancy because of its rapid progress and high mortality rate.
30 
 
Causes can be hereditary as a result of an inherited deficiency in ADAMTS13 (an enzyme 
needed for cleavage of VWF); or acquired as an autoimmune response against 
ADAMTS13.
30   
The deficiency results in activation of VWF and attracts and activates 
platelets, causing obstruction of small calibre vessels and ischaemia, resulting in end organ 
damage.
30  
Some patients with the inherited condition can present for the first time in 
pregnancy as pregnancy is one of the known triggers, causing confusion with features of pre-
eclampsia or HELLP syndrome.
21,30
  
 
Treatment is by plasma exchange and attention to the 
precipitating cause.
22,38   
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1.6.4 Haemolytic uraemic syndrome  
The clinical picture of haemolytic uraemic syndrome is similar to TTP except for the 
presence of significant renal dysfunction.
21
  Features of bloody loose stool may also be 
present if Shigella is the causative organism.
21 
 
1.6.5 Immune thrombocytopenic purpura 
Immune thrombocytopenic purpura (ITP) should be the last in the list of differential 
diagnoses in a patient with thrombocytopaenia in pregnancy.
21  
ITP is autoimmune mediated, 
possibly triggered by drugs, connective tissue diseases or infections.
21 
 Treatment is achieved 
by treating the underlying cause as well as platelet transfusion, immunoglobulins, and 
immunosuppressive agents.  Splenectomy is indicated in patients with a poor response to 
medication.
21 
 
1.6.6 Pre-eclampsia
 
Thrombocytopaenia is one of many complications associated with pre-eclampsia and occurs 
typically in 10% of cases.
31
  However, a cohort study by Burrows et al. found an incidence 
approximately five times higher, reporting a 50% occurrence rate in their pre-eclamptic 
population – this 50% occurrence rate is also supported by Leduc et al.32,33  The authors of 
the two studies suggested that the abnormally high incidence was because the study 
population only included those with pre-eclampsia severe enough to require intensive care 
admission.  The thrombocytopaenia can be isolated (apart from clinical evidence of pre-
eclampsia) or can occur as part of the HELLP syndrome.
34
  The platelet count improves 
within a few days after delivery. 
16 
 
1.6.7 Haemolysis, elevated liver enzymes, low platelets syndrome 
Haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome is a severe form of 
pre-eclampsia in which the pathophysiology and risk factors are mostly similar.
21
  The 
difference is in the microangiopathy that occurs in HELLP syndrome.
21
  In addition to 
thrombocytopaenia, haemolysis is evident on peripheral smear, showing schistocytes and 
spherocytes, with elevated serum lactate dehydrogenase.  Elevated transaminase levels are 
observed and hyperbilirubinaemia may occur.
21 
 Hypertension is not present in up to 20 % of 
cases.
21 
  Endothelial dysfunction is believed to cause the reduction in the platelet count by 
causing platelet aggregation and destruction.
21
  Similarly to pre-eclampsia, the platelet count 
will also improve after delivery. 
 
1.6.8 Acute fatty liver in pregnancy 
Acute fatty liver, which is also a microangiopathic haemolytic condition, is also in the list of 
differentials for HELLP syndrome as it presents with right upper quadrant pain, moderate 
thrombocytopenia, elevated liver enzymes and renal failure, elevated conjugated bilirubin 
(frequently > 5mg/dL), and coagulopathy.
35 
 
1.6.9 Disseminated intravascular coagulopathy  
Disseminated intravascular coagulopathy (DIC) is a consumptive coagulopathy, triggered by 
an assortment of pathologies.  In the obstetric setting the causes include sepsis, haemorrhage, 
intrauterine fetal death, amniotic fluid embolism, abruptio placentae and eclampsia.
36
  These 
triggers lead to activation of the coagulation system.   Haematological parameters in DIC 
include prolonged International normalised ratio (INR) and partial thromboplastin time 
17 
 
(PTT), thrombocytopenia, low fibrinogen levels and elevated D-dimers.
37
  If the triggers of 
DIC are not treated, pathology may progress and cause consumption of factors V and VIII in 
the clotting cascade as well as platelets, all resulting in increased fibrin deposition, 
thromboembolism and tissue ischaemia.
37 
 Fibrinolysis follows with formation of fibrin 
degradation products and haemorrhage is consequent on clotting factor and platelet 
consumption.
37
  HELLP syndrome and pre-eclampsia are often included in the differential 
diagnosis of DIC.
37
  In mild cases, the diagnosis may be difficult in pregnancy as some of the 
clotting parameters change as part of a normal physiological response to pregnancy, for 
example D-dimers being elevated.
37 
 
1.7 Why platelet counts drop in pre-eclampsia 
Investigations concerning the mechanism and pattern of thrombocytopenia in pre-eclampsia 
were popular, mainly in the 1980s and 1990s, predominantly among American authors.  
There are few articles published after 1995, and these articles typically quote the older ones. 
Studies had differing conclusions and about three decades later few newer findings have 
arisen. Theories for the pathogenesis of thrombocytopaenia include increased platelet 
activation, increased destruction likened to DIC, an immune component, dysfunctional 
platelets as one of the causes of pre-eclampsia, reduced platelet life span through 
microangiopathic haemolytic processes, and increased turnover.
38
 
 
1.7.1 Abnormal increase in platelet activation  
The most common theory for thrombocytopaenia in pre-eclampsia is that of increased platelet 
activation.
39   
The actual trigger remains unclear, but is thought to be abnormal eicasanoid 
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production related to placental dysfunction.
39,40
  Studies have aimed to prove this theory by 
demonstrating an increase in markers that rise during platelet activation.  Some of the 
markers include raised levels of the compound urinary 11-dehydrothromboxane b2/mg 
creatinine, B-thromboglobulin, platelet factor 4, CD63, CD62P, fibrinogen antigens and 
increased platelet volume.
40,41,42  
 
 
Hayashi et al. in 2002 conducted a study on 99 women, investigating five markers that would 
accurately represent the link between the endothelium, coagulation and pre-eclampsia.
41
  
With regard to platelet count trends in pregnant women who have pre-eclampsia with 
thrombocytopenia, Hayashi et al. used urinary 11- dehydrothromboxane b2/mg creatinine, B-
thromboglobulin and platelet factor 4 as markers of platelet activation.  Thromboxane B2 is a 
metabolite of thromboxane A2 which is an activator of platelets.  Unlike Thromboxane B2 in 
blood, Urinary 11-dehydrothromboxane B2 is thought to be more stable and a more accurate 
representation of thromboxane levels as it is not affected by blood aspiration.  Creatinine 
ratio is included in the measurement because urine output can affect the thromboxane 
levels.
41
  The authors found that the median platelet count decreased as it progressed from the 
non-pregnant controls, to pregnant patients with normal blood pressure, to those with mild 
and severe pre- eclampsia.  These findings where statistically significant (p<0.05).
41 
 
Interestingly, the progressive decrease of platelet count coincided with an increase in urinary 
11-dehydrothromboxane b2/mg creatinine, B-thromboglobulin and platelet factor 4, 
suggesting that the decrease in platelet count was related to platelet activation.
41 
 The increase 
in platelet factor 4 was only statistically significant in the severe pre-eclamptic group, and the 
increase in B-thromboglobulin and urinary 11 dehydrothromboxane b2/ mg creatinine was 
only statistically significant compared to the non-pregnant control (p<0.05).
41
  Hayashi et al. 
used strict criteria to decrease the chances of measurement bias by excluding those with 
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comorbid disease that would impact on hypertension, and ensured a detailed and standardised 
method for urine and blood collection.
41
  On the other hand, Major et al. (2015) found no 
features suggestive of platelet activation in pre-eclampsia.
42
  Major et al. conducted a small 
study that found an increase in platelet factor 4 levels in both pre-eclamptic and normotensive 
pregnant patients, suggesting that it was pregnancy rather than pre-eclampsia alone that 
resulted in an increased level.
42
   
 
Janes et al. in 1994 aimed to clarify the differences in platelet behaviour expressed in various 
studies in pre-eclampsia by adding whole blood flow cytometry methods to measure platelets, 
in addition to blood aggregometry and measurement of B-thromboglobulin levels.
40 
 Blood 
aggregometry and measurement of B-thromboglobulin levels are the usual methods used by 
researchers to assess platelet behaviour.  The two methods have been criticised because 
platelet results are affected by the manner in which the blood sample is collected and 
measured.
40
  Flow cytometry is considered superior.
40 
 Janes et al. analysed the blood of 55 
women categorising them into four groups: non pregnant, pregnant normotensive, 
hypertensive and  pre-eclamptic, and measured the platelet count, B-thromboglobulin, as well 
as CD63 antigen and fibrinogen antigens (the last two are antigens that become exposed on 
the surface of the platelet membrane after structural changes associated with platelet 
activation).  In agreement with Hayashi et al., Janes et al. found elevated  B-thromboglobulin 
levels in the  hypertensive (75 μg/l) and pre-eclamptic groups (81 μg/l) , compared to the 
non- pregnant group ( 42 μg/l)  (p < 0.01).  They also found higher  B-thromboglobulin  
levels expressed per platelet in the hypertensive and pre-eclamptic groups (0.39 μg/109 
platelets and 0.46 μg/109 platelets) compared to the non-pregnant controls (0.26 μg/109 
platelets)  (p-< 0.01).
40 
 The criticism of Janes et al. is that their definition of pre-eclampsia 
was inconsistent with the definitions used by the recognized societies mentioned previously. 
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It should be noted, however, that this work was published two decades prior to the ISHHP 
document. 
 
Increased expression of cell adhesion molecules such as CD62P and CD63, as well as 
increased binding of activated platelets to neutrophils and monocytes, and increased platelet- 
derived microparticles have also been used as markers of increased platelet activation.  
Macey et al. in 2010 found higher amounts of CD62P in pre-eclamptic women (0.8%) 
compared to normotensive pregnant women(0.3%), and higher platelet monocyte aggregate 
formation of  2.8% in the normotensive compared to 4.8% in the pre-eclamptic group 
(p<0.05).
43 
 Results from a London-based case control study also supported findings of 
Macey et al.
40
  Evidence of increase in platelet-derived microparticles was not supported by 
Van Wijk in 2002 nor by Lok et al. in 2008.
45,46
  In contrast, they found decreased levels of 
microparticles.
45,46 
 Lok et al. suggested that the lower levels of microparticles could have 
been related to the overall low platelet count in the pre-eclamptic women; both studies used 
only small samples of women.
45,46
  
 
Ceyhan et al. in 2006 investigated 100 patients comparing full blood count and mean platelet 
volume in mild and severe pre-eclamptic and normotensive pregnant patients.
47
 The increased 
platelet volume is believed to represent increased production of immature platelets, this 
increased production in response to increased demand and platelet activation.  Ceyhan et al. 
found no statistically significant difference in the platelet count nor mean platelet volume, in
 
the normotensive or pre-eclamptic groups.
47 
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Overall, the results of increased platelet activation as a cause for reduced platelets in pre-
eclampsia seem convincing.  However, the numerous potential markers make it difficult for 
researchers to decide which one is most accurate.  Research comparing the efficacy of each 
test may be helpful in the future. 
 
1.7.2 Initiating factor of pre-eclampsia 
A review by Redman et al. in 1990 raises the question as to whether the reason for a decrease 
in platelet count in pre-eclampsia is because platelets actually play a role in the aetiology of 
pre-eclampsia.
48 
 Redman et al. refer to a study that was conducted by Zemel et al. in 1990 to 
find out whether increased release of free calcium stored in the cytoplasm of platelets 
precedes the clinical manifestations of pre-eclampsia.
49 
 Calcium is a secondary messenger 
involved in the activation of platelets.  Increased release of free calcium within platelets 
would indirectly imply increased activation of platelets.
48
  Redman et al. conducted a follow-
up study on 48 women measuring their platelet intracellular ionised calcium levels at the end 
of the first trimester, at 25 weeks, and at 34-36 weeks, and found that of the 14 women who 
later developed pre-eclampsia, 11 showed increased intracellular free calcium within platelets 
after the addition of arginine vasopressin (p<0.01), well before the onset of clinical 
preeclampsia.
48 
 Konijnenberg et al. in 1997 used a different method to test whether platelets 
were involved in pre-eclampsia aetiology.
50 
 They measured P-selectin, platelet endothelial 
cell adhesion molecule and the cell adhesion molecule CD63, aiming to show that these 
markers of  platelet activation would be increased early in those destined to complicate with 
pre-eclampsia.
50 
  Konijnenberg et al. conducted their study on 244 pregnant women from 13 
weeks gestation and found that of the 17 who developed pre-eclampsia, eight had increased 
first trimester CD63 expression, implying that increased CD63 levels could be used to predict 
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pre-eclampsia.  They used a percentage of activated platelets above 2% as reference of a 
positive test of risk association, and the 2% cut off was considered to yield the highest 
sensitivity and specificity.
50
  However, the sensitivity and specificity were low (47% and 
76% respectively) with a poor likelihood ratio of 1.94 for predicting pre-eclampsia.
50  
P-
selectin and platelet endothelial cell adhesion molecule were not found to be raised early on 
in the pre-eclamptic group.  
 
It has proved difficult to implicate platelet activation early in the pregnancies, before clinical 
onset of pre-eclampsia as a cause of pre-eclampsia rather than a complication. If platelets are 
involved early in the pathogenesis of pre-eclampsia, one would expect an increase in most or 
all markers of platelet activation in advance of clinical pre-eclampsia disease.  The laboratory 
markers investigated so far do not appear to be useful for screening or early detection of pre-
eclampsia.    
 
1.7.3 Immune component 
The presence of increased platelet associated IgG in Burrows et al.’s prospective study from  
1987 may suggest an immune component to platelet destruction.
32 
 They monitored 61 
pregnant patients with pre-eclampsia and 25 normotensive patients, and found that about one-
fifth of pre-eclamptic patients had elevated levels of platelet associated IgG, and in this group 
42.5% had thrombocytopenia.
32  
None of the normotensive patients showed elevated levels of 
IgG.
32
  However, the findings by Burrows et al. failed to support this theory entirely because 
25% of patients with pre-eclampsia without thrombocytopenia also demonstrated elevated 
IgG.
32   
Whether this may be an early sign of future thrombocytopenia is not clear. There is 
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insufficient evidence to suggest an immune component as there appears to be no further  
research published regarding this matter.
 
 
1.7.4 Subclinical activation of the coagulation system and disseminated intravascular    
coagulopathy 
A review by Letsky el al. stated that the finding of a low platelet count in the absence of 
antiplatelet antibodies in pre-eclampsia could suggest the presence of a mild consumptive 
coagulopathy.
36 
 This coagulopathy has been likened to DIC in a study conducted by Heilman 
et al. in 2007 where they measured factors that affect coagulation, including platelet count 
and D-dimers from the blood of 111 women with early and late onset pre-eclampsia, and 
compared these to 33 healthy pregnant women.
51
  They found that in the group with early 
onset pre-eclampsia, a low platelet count <50x10
9/
L corresponded with an increased D-dimer 
(r = −0.578, p <0.05).51  Heilman et al. failed to demonstrate this correlation in the group with 
late onset pre-eclampsia and the study did not measure the INR or PTT, which would have 
provided the other necessary parameters to diagnose a DIC.
51 
 In their study, Leduc et al. in 
1992 also aimed to determine if there were other markers in the coagulation cascade that 
would be abnormal if the platelet count was low in women with pre-eclampsia.
33  
The 
findings of Leduc et al. disproved DIC as a cause of thrombocytopenia in pre-eclampsia by 
demonstrating that out of the 50 patients who had platelet counts <150 x10
9 
/L, 17 had low 
fibrinogen levels (300mg/dL) and increased INR and increased fibrin degradation products 
only occurred in 2 of these cases; both of which had platelets below 50 x10
9/L
.
33
  Janes et al. 
also supported the findings of a negative association of DIC and thrombocytopenia by Leduc 
et al. by demonstrating higher fibrinogen levels in the pre-eclamptic compared to the 
normotensive and non-pregnant group, (4.8g/dL and 3.8g/dL ) (p< 0.01).  They also found no 
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other abnormalities in INR or PTT.
40  
DIC as the cause of thrombocytopenia in pre-eclampsia 
appears to be unlikely, but a mild form may contribute in the pathogenesis of pre-eclampsia 
in its entirety.
 
 
1.7.5 Damage by activated endothelium 
There are suggestions that abnormal endothelial structure and function associated with pre-
eclampsia is a cause of a low platelet count
52
  In their prospective study analysing the 
relationship between reduced prostacyclin biosynthesis and pregnancy-induced hypertension, 
Fitzgerald et al. in 1990 found that the endothelium produced less 2, 3-dinor-6-keto-PGF (a 
prostacyclin metabolite) and more thromboxane in women with pre-eclampsia compared to 
their normotensive counter parts.
53
  Thromboxane is primarily produced by the endothelium 
and its main effects include vasoconstriction and platelet activation and aggregation , with 
increased levels associated with pre-eclampsia all these effects are amplified.
53
  Abnormal 
endothelium may result in platelet adherence to the endothelium destroying the platelets by 
shear forces, and this is believed to occur as a microangiopathic haemolysis in HELLP 
syndrome.
53 
 Another possibility is that the platelet count drops as platelets aggregate in areas 
of endothelial damage to aid with healing and thrombus formation with increased deposition 
of thrombin.
52 
 Another theory is
 
that the life span of the platelet is reduced by 3-5 days 
because of changes in the structure of the platelet, and that this abnormal morphology results 
in the premature destruction of platelets.
52,53 
 All these findings suggests a combination of 
increased platelet activation, aggregation and destruction as a cause of low platelet count in 
pre-eclampsia. 
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1.8 Platelet count trends in pre-eclampsia 
There is little literature regarding platelet trends in pre-eclampsia.  Leduc et al. in 1992 
conducted a retrospective study where they reviewed the files of 100 women diagnosed with 
pre-eclampsia or chronic hypertension with superimposed pre-eclampsia.
33 
 Platelet counts 
were measured within 2 hours of admission then 6 hourly thereafter.
33
  They found that half 
of these patients had thrombocytopenia as a complication.
33  
They then used a regression 
equation to analyse the platelet count on admission and see whether it would determine the 
lowest platelet count drop later on.
33 
 They found that if the platelet count on admission was 
<200x10
9
/L, there was 50% confidence that the lowest platelet count would be <150x10
9
/L. 
They also found that if the platelet count was<100x10
9
/L on admission, the subsequent 
platelet count had a 75% likelihood of dropping below 100x10
9
/L, even as low as 50x10
9
/L 
(p<0.01).
33 
 The findings suggested that platelet counts dropped in pre-eclampsia, and that the 
lower the platelet count, the greater the likelihood of further decreases.  
 
A study conducted by Rinehart et al. in 2001 aimed to determine whether the initial platelet 
count and LDH level could identify patients in whom disease progression would occur as 
well as the rate at which it would occur.
55 
 The study recruited patients with HELLP 
syndrome and with severe pre-eclampsia.
55 
 The authors further categorised patients with 
HELLP syndrome into three groups depending on lowest platelet counts recorded at the time 
of delivery: class 1 had counts <50x10
9
/L, class 2 with 50-100x10
9
/L and class 3 from 100-
150x10
9
/L.
55 
 They recorded the platelet count on admission, two hours prior to delivery, 
during labour and in the post-partum period.
55 
 Firstly, regarding the platelets, they found that 
only 10% of the 639 patients reached the lowest platelet count prior to delivery, the majority 
reaching the platelet nadir in the post-partum period (61%).
55 
 The second finding was that 
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patients whose platelet count reached <50 x10
9
/L prior to delivery had the fastest rate of 
decline over the 2 days prior to this measurement (a rate of 50x0
9/
L/day).
55
  The rate of 
decline was significantly less if the platelet count was >50x10
9
/L. This accords with the 
findings of Le Duc et al.
33
  The study failed to demonstrate what the initial platelet count was.  
What is therefore missing is prospective work to predict platelet count declines in women 
with pre-eclampsia and thrombocytopaenia.
 
  
1.9 Antenatal corticosteroid medication
 
Glucocorticoid drugs are anti-inflammatory and immune-suppressive in nature, and it is 
therefore reasonable for researchers to believe that these drugs can counteract the 
pathophysiological process of pre-eclampsia and its complications.
56 
 With HELLP 
syndrome, these steroids are believed to inhibit platelet adhesion and decrease splenic 
sequestration of damaged platelets.
56 
 Martin well known for his research in corticosteroids 
and pre-eclampsia conducted a study in 2003 regarding the benefits of steroids in HELLP 
syndrome and found that intravenous administration of high dose (10mg) dexamethasone 12 
hours apart resulted in fewer maternal complications, including a higher mean platelet count 
of 65x10
9
/L compared to the 55x10
9
/L in the group who had received a lower dose of steroids 
(p<0.01).
57
  A Cochrane Review did not find such benefit and showed that there were 
limitations to this study as well as other studies that show benefit of steroids.
58
   The review 
noted that the trials did not compare steroids to placebo, that they gave the patients either 
medication or none at all, some had small sample sizes, different types and doses of steroids 
were used, and the definitions of HELLP syndrome differed between the studies.
58
  There is 
however still uncertainty about the therapeutic role of steroids in HELLP syndrome. 
Improvement of the platelet count due to steroids alone seems unlikely.  
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1.10 Platelet count cut-offs for regional anaesthesia 
 
The platelet cut off for safe administration of regional anaesthesia is controversial.  A review  
by Loo et al. stated that the greatest concern in performing regional anaesthesia on a patient 
with coagulation abnormalities is the development of haematoma and associated neurological 
sequela, should the venous plexuses be punctured.
59 
 What makes the topic controversial is 
that the incidence of neurological complications appears to be low having been recorded in a 
few case series and retrospective file reviews with an incidence of 0.2-3.7/100 000 in epidural 
blocks and 5 per million in a general population undergoing spinal anaesthesia in the United 
Kingdom.
59 
 But anaesthetic researchers are understandably reluctant to conduct 
interventional research  to confirm the lowest platelet count cut off, and would rather perform 
general anaesthesia in these patients.  The known cut off of 75-80x10
9
/L, is believed to have 
originated from Orlikowski et al. study from 1996, where they measured the platelet count, 
bleeding time and thromboelastography(used to monitor the characteristics of a clot) in 49 
pre-eclamptic and eclamptic women.
60 
 Orlikowski et al. found that a platelet count 
<54x10
9
/L suggested a reduced ability for clot formation to be preserved (95% confidence 
interval of 40-75x10
9
/L).
60 
 Rucklidge and Paech (2001) reviewed the files of 9735 women 
who had received regional anaesthesia, of whom 47 had platelet counts from 75-100x10
9
/L 
and 13 had platelet counts<75 x10
9
/L.
61
  The retrospective review by Rucklidge and Paech 
found that none of these patients had neuraxial haematoma as a complication.
61 
 Pre-
eclampsia was the second most common cause of the thrombocytopenia (26%) in the study 
population.
61
  Beilin suggests a lower platelet count of 50-100x10
9
/L as safe for regional 
anaesthesia, and states that the findings are also recommended by the ACOG.
62 
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The majority of anaesthetists agree that regional anaesthesia can be administered with a 
platelet count below 100x10
9
/L but the lowest value has yet to be confirmed.  
 
1.11 Platelet count cut-offs for prophylactic platelet transfusion at delivery 
Prophylactic administration of platelets prior to surgery to prevent blood loss in patients with 
low platelets is also controversial.  Platelet transfusions like all blood products has associated 
risks, is expensive, and supply is limited.
63 
 The cut off level of <50x10
9
/L for patients 
undergoing invasive procedures such as surgery is rather arbitrary and is based on level 4 
evidence from the opinion of experts and a small number of case series.
64 
 Original research 
concerning prophylactic platelet transfusion, irrespective of subsequent surgery, was 
conducted by Gaydos et al. in the 1960s where they reviewed the files of 92 patients with 
leukaemia aiming to see at what level the platelet count would correlate with spontaneous 
haemorrhage.
65 
 They found that haemorrhage was least likely to occur if the platelet count 
was >20x10
9
/L.
65 
 Gaydos is credited with the original data that has led clinicians to use a 
platelet count of >20x10
9
/L as an indication for prophylactic platelet transfusions to prevent 
spontaneous bleeding.
65 
 The suggestion of transfusion with platelet counts <50 x10
9
/L for 
those undergoing surgical intervention remains an arbitrary one based on expert opinion 
guidelines and  a limited amount of research.
 66
 The most data collected regarding major 
surgery on patients with thrombocytopenia was in 1987 by Bishop et al. 
67  
Bishop and 
colleagues reviewed the files of 95 patients with leukaemia who had a surgical procedure 
(majority were laparotomies and craniotomies) and found that in the group where platelets 
were >50x10
9
/L, significant blood loss of more than 500 mL and need for significant blood 
transfusion of four units occurred  in only 7% of cases.
 67
 Limitations of Bishop et al. work 
was its retrospective nature and lack of a comparative arm.  In 1990 McVay retrospectively 
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analysed the files of patients who had liver biopsies and recorded an incidence of significant 
haemorrhage in 3.4% of the patients with platelets of 50-99x10
9
/ L; this figure was similar to 
those patients who had liver biopsy with normal blood results.
68
  These findings, although of 
poor quality, support a platelet count of >50 x10
9
/L as safe to proceed with some surgical 
procedures, including caesarean section, without needing to resort to prophylactic platelet 
transfusion. 
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2. PROBLEM STATEMENT AND MOTIVATION FOR RESEARCH
 
A low platelet count is a marker of disease severity and is an indicator of poor prognosis for 
both mother and fetus in women with pre-eclampsia and related syndromes. The platelet 
count is therefore used in clinical management decisions such as admission to high care area 
and early delivery of the fetus.  Once a patient with a low platelet count has been identified, 
there is understandably concern that the platelet count will fall further, to the point of causing 
bleeding complications, either during spinal or epidural analgesia, or at caesarean section. In 
the absence of frequent serial testing of platelet counts in such patients, clinicians may make 
assumptions about the platelet count trend. Such assumptions can affect clinical management  
of patients in the following ways:  
 
1. General anaesthesia preferred over regional analgesia in patients with platelet counts >75 
x10
9
/L, based on the concern that such platelet count will have fallen to below this level by 
the time anaesthesia is given. General anaesthesia itself is not without hazard in these 
patients, and complications include aspiration of stomach contents as well as acute severe 
hypertension.
69
  
 
2. Prophylactic platelet transfusions given to patients with platelet counts >50x10
9
/L before 
caesarean section. The belief, again, is that the platelet count would have fallen to <50x10
9
/L 
by the time caesarean section starts. Besides the cost of transfusion, there is always a small 
risk of transfusion-related complications.  
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3. Longitudinal skin incisions made in pre-eclamptic women with a low platelet count to 
decrease blood loss associated with injury of abdominal wall vessels with a transverse 
incision.  Besides cosmetic objections, higher rate of post-operative pain and incisional hernia 
have been shown for patients undergoing vertical skin and sheath incisions.
70 
 
 
4. The fetus delivered prematurely if the platelet count is >100x10
9
/L, in anticipation of a 
drop in platelet count to <100x10
9
/L. This is done rather than repeating the blood test and 
waiting for a result.  Premature delivery increases the infant’s length of admission, likelihood 
of admission to an intensive care unit and increased risk of preterm birth complications.
71
   
 
2.1 Purpose of the study 
Only two studies could be found that considered platelet count trends in pregnant women 
who have pre-eclampsia with thrombocytopaenia. This study was done to prospectively 
identify patients diagnosed with pre-eclampsia and who have thrombocytopaenia, and follow 
their platelet counts while still pregnant to identify a predictable trend. Based on the results of 
this study, more educated predictions or resisting the temptation to predict the platelet count 
may decrease the need for unnecessary expense involved, such as mentioned in the four 
situations discussed above.   
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2.2 Objectives of the study 
1. To describe platelet counts on admission to hospital in women with pre-eclampsia 
who have thrombocytopaenia and who have follow-up platelet counts performed 
while still pregnant. 
2. To describe demographic and clinical factors in women admitted with pre-eclampsia 
who have thrombocytopaenia and who have admission and follow-up platelet counts 
performed while still pregnant. 
3. To describe follow-up platelet counts in these women while still pregnant and observe 
any trend in the platelet count. 
4. To identify factors associated with trends in platelet count in these women. 
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3. METHODOLOGY 
3.1 Definitions of key terms (adapted from the ACOG  guidelines)  
Pre-eclampsia: elevated blood pressure of ≥140/90 mmHg on ≥2 occasions (readings should 
be taken at least 4 hours apart), and significant proteinuria ≥300 mg collected in a 24 hour 
specimen or  ≥1+ proteinuria on test strips, had no history of chronic hypertension and who 
were normotensive at antenatal booking and non-proteinuric. The definition for this study 
allows inclusion of women who presented for antenatal care after 20 weeks of gestation and 
were normotensive at the time.  
  
Severe pre-eclampsia:blood pressure ≥160/110 mmHg on two or more occasions at least 4 
hours apart or a once-off diastolic blood pressure ≥120 mmHg, or proteinuria ≥5g over a 24 
hour period or persistently ≥3+ proteinuria on test strips.   
Or  
New-onset elevated blood pressure after 20 weeks of pregnancy with at least one of the 
following features: 
• Features of imminent eclampsia 
• Neurological or visual disturbances such as severe headache, hyper reflexia and 
seizures 
• Epigastric or right upper quadrant pain   
• Pulmonary oedema or central cyanosis 
• Impaired liver function AST ≥40U/L 
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• Thrombocytopenia <150x109/l or evidence of haemolysis (Mississippi classification 
used).
69 
• Features of placental insufficiency and intra uterine growth restriction  
• Renal dysfunction with creatinine >100μmol/L, urine output <500 mL in a 24 hour  
period or urea >8 mmol/L 
 
3.2 Research design and ethics 
The study was a cohort design, with data collected prospectively.  Patients were recruited at 
all three academic hospitals attached to the University of the Witwatersrand. No interventions 
were done, and all platelet count results used were from blood tests done as part of the 
management of each patient. Permission to undertake the study was obtained from the 
Human Research Ethics Committee of the University of the Witwatersrand (certificate 
number M130737, attached as Appendix D), and from the Chief Executive Officers of the 
three academic hospitals.  
 
3.3 Study population 
The study population was women with pre-eclampsia, including HELLP syndrome, found to 
have, on admission to hospital, a platelet count <150x10
9
/L (thrombocytopaenia), or who 
developed thrombocytopaenia while admitted to hospital.  Women had to have two or more 
platelet counts estimated while pregnant, from entry into the study up to delivery. Because of 
the local high proportion of women who book late (after 20 weeks) for antenatal care, the 
definition of pre-eclampsia was extended to include women who booked after 20 weeks of 
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gestation,  who had no history of chronic hypertension and who were normotensive and non-
proteinuric at booking.  
Exclusion criteria: 
• Gestational age <20 weeks  
• Intrauterine fetal death 
• Abruptio placentae  
• Eclampsia 
• Connective tissue or autoimmune disorders  
• Advanced HIV disease (World Health Organization stage 4) 
• Acute infections 
• Platelet transfusions received before the second platelet count 
• Anticoagulant medication 
• Haematologic disorders resulting in low platelet counts, e.g. VWF disease 
• Microangiopathies other than HELLP syndrome, e.g. haemolytic uraemic syndrome, 
thrombotic thrombocytopaenic purpura 
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3.4 Sampling 
The researcher, a registrar in Obstetrics and Gynaecology, had time on certain days of her 
rotation at the various hospitals to collect data for this study. On such days, she identified all 
women potentially eligible for the study admitted during the previous 24 hours (pre-eclamptic 
with thrombocytopaenia), and obtained informed consent from them to be included in the 
study.  The women were followed up for later platelet count results and clinical course.  The 
sample was therefore a period sample restricted to days that the researcher was available to 
collect data.  The initial plan was to recruit about 100 participant women for the study.   
 
Gestational age was calculated using the best estimate.  Early ultrasound scan (before 24 
weeks) was the preferred method for calculation.  In the absence of early scanning, the last 
menstrual period was used next, failing which late ultrasound or clinical assessment was 
used. 
 
Steroids administered in anticipation of preterm birth were betamethasone 12mg 
intramuscular injections two doses 12 hours apart.  The administration of steroids was 
recorded in relation to the time that the second platelet count was obtained.  Steroids are not 
used at Wits teaching hospitals to treat HELLP syndrome. 
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3.5 Data collection techniques 
The researcher went to the obstetric high care area and identified patients diagnosed with pre-
eclampsia who had thrombocytopaenia, and excluded those found under the exclusion criteria 
list.  The included patients were then followed up in the antenatal and post-natal wards. 
 
The researcher explained the research, using an interpreter if needed, and obtained consent to 
look through patients’ hospital files while they were in the ward to make sure that they met 
the criteria of pre-eclampsia and thrombocytopaenia and recorded this information in the data 
sheet (Appendix A, B, and C).  The researcher then recorded their hospital numbers and 
checked on the NHLS computer for platelet count results.  She continued to check any further 
results of platelet counts until they were discharged.  The patients were chosen from all three 
Wits academic hospitals, depending on the researcher’s work rotation.  The time interval 
taken between subsequent platelet counts was not set, as this was determined by clinical 
decisions of the staff on duty.  The time interval between platelet count tests was determined 
by using the time that the blood sample specimen was entered on the computer in the NHLS 
laboratory.  The researcher recorded all information on a data collection sheet and transferred 
it to Microsoft Excel. 
 
The following data were collected: 
• Demographics: age, gravidity and parity, gestational age at time of first antenatal 
booking, blood pressures and urine test strips on booking. 
• HIV status, CD4 counts HIV WHO classification, antiretrovirals used. 
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• Presence of medical disorders such as diabetes mellitus. 
• The use of aspirin, nifedipine, methyldopa and/or magnesium sulphate. 
• Highest blood pressure and proteinuria during admission, and clinical or biochemical 
complications associated with pre-eclampsia. 
• Features of placental insufficiency. 
• Severity of pre-eclampsia. 
• Administration of steroids for anticipated preterm birth. 
• The platelet count reading on admission and the subsequent platelet count. 
• Date and time, mode and outcome of delivery. 
 
3.6 Data analysis 
Data from Microsoft Excel were imported to Stata 11 statistical software (Statacorp, College 
Station, Texas, USA).  Categorical variables were reported as proportions with percentages, 
and continuous variables were reported as means with standard deviations or medians with 
ranges.  Differences in platelet counts were treated as continuous variables.  Comparisons of 
first and subsequent platelet counts were made using Student’s t-test for unpaired normally 
distributed data or Wilcoxon’s signed rank test for paired skewed data.  A p value <0.05 was 
accepted as indicating statistical significance.   
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4. RESULTS 
4.1 Demographic information 
Thirty two women were included in the study.  The mean age of the women was 27.1 years 
with a range of 18-36 years.  Sixteen (50%) were from Rahima Moosa Mother and Child, ten 
(31%) from Chris Hani Baragwanath Academic and six (19%) from Charlotte Maxeke 
Johannesburg Academic.  Fourteen (44%) were nulliparous.  Using the best gestational 
estimate, 14 women (44%) had booked for antenatal care before 20 weeks gestation.  None 
were hypertensive at booking.  All women received anti-hypertensive drugs in the antenatal 
period, either nifedipine or methyldopa or both.  Sixteen of the women (50%) were between 
28 to 33 weeks pregnant at the time of admission.  Thirteen women had symptoms and signs 
of imminent eclampsia (Table 1).  A diagnosis of HELLP syndrome was made by the 
attending clinicians in 14 of the women. However, only four women of the 32 were tested for 
evidence of haemolysis (either lactate dehydrogenase level, haptoglobin level or peripheral 
smear).  Of the four women tested, only one had HELLP syndrome confirmed (on smear and 
with haptoglobin level). 
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Table 1. Demographic and obstetric data for pre-eclamptic women with low platelet 
counts who had repeat platelet counts done before delivery (number (%) or 
mean±standard deviation) (n=32). 
Hospital:      
                    Rahima Moosa Mother and Child 
                    Chris Hani Baragwanath Academic 
                    Charlotte Maxeke Johannesburg Academic 
 
16 (50.0%) 
10 (31.0%) 
6 (19.0%) 
Age (years)      
 
27.1±5.3 
Parity:          
                    0 
                    1 
                    ≥2 
 
 
14 (44.%) 
12 (37.5%) 
6 (18.5%) 
Women who booked for antenatal care at <20 weeks 
 
14 (44.0%) 
HIV infected 
 
4 (12.5%) 
Diabetes mellitus 
 
0 (0.0%) 
Twin pregnancy 
 
1 (3.0%) 
Gestational age on admission: 
                    <28 weeks 
                    28-33 weeks 
                    ≥34 weeks 
 
 
2 
16 
14 
Women who received antenatal antihypertensive medication 
 
32 (100.0%) 
Women who received antenatal corticosteroids (betamethasone): 
                    No doses 
                    Incomplete dosage (12 mg) 
                    Full dosage (24 mg) 
 
 
14 
6 
12 
Highest pregnancy systolic blood pressure (mmHg) 
 
175±20 
Highest pregnancy diastolic blood pressure (mmHg) 
 
106±13 
Proteinuria on urine reagent strips: 
                    1+ 
                    2+ 
                    3+ 
 
4 
7 
21 
Antenatal pulmonary oedema 
 
0 
Antenatal imminent eclampsia symptoms or signs 
 
13 
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4.2 Delivery outcomes 
 
Thirty-one (96.9%) of the women delivered by caesarean section.  The median duration 
between the last platelet count taken and delivery was 3.8 hours.  Twenty-five of the babies 
weighed <2500 g at birth.  There were no maternal deaths or admissions to the intensive care 
unit (Table 2) 
 
Table 2. Delivery data for pre-eclamptic women with low platelet counts who had repeat 
platelet counts done before delivery (number (%) or median (interquartile range); n=32 
women and 33 babies). 
Mode of delivery: 
                    Caesarean section 
                    Vaginal birth 
 
 
31 (96.9%) 
1 
Time interval between last platelet count and delivery (hours) 
 
3.8 (2.1-8.9) 
Birth weight categories: 
                    <1000 g 
                    1000-2499 g 
                    ≥2500 g              
 
 
4 
21 
8 
Babies small for gestational age 
 
7 
Birth outcome: 
                    Live birth 
                    Stillbirth 
                    Early neonatal death 
 
 
31 
0 
2 
Maternal death or admission to adult intensive care unit  
 
0 
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4.3 Platelet count results 
The median first platelet count on admission into the study was 112x10
9
/L and the next 
platelet count was 99x10
9
/L) (p=0.78).  The median time interval between first and second 
platelet counts, and haemoglobin levels, was 19.3 hours (interquartile range 8.8-23.9).  Ten 
percent of time intervals exceeded 48 hours.  There was no significant difference for 
difference between second and third platelet counts (n=14, p=0.49).  There was no significant 
difference in first and second haemoglobin levels (n=27; p=0.62).  AST levels were estimated 
in 24 women, and 12 had AST levels ≥40 U/L (Table 3). 
 
Table 3. Platelet count (x10
9
/L) at first, second and third testing, haemoglobin levels 
(g/dL) at first and second testing, and aspartate transaminase levels (IU/L) and 
creatinine levels (μmol/L  during admission to hospital (median and interquartile 
ranges), with P value given for differences where applicable. 
 Median (interquartile 
range 
P value* 
First platelet count (n=32) 
Second platelet count (n=32) 
112 (79-137) 
99 (70-130) 
0.78 
Third platelet count (n=14) 
 
100 (76-128) NA 
Fourth platelet count (n=6) 
 
142 (65-163) NA 
First haemoglobin level (n=30) 
Second haemoglobin level (n=27) 
12.7 (11.3-13.5) 
12.4 (11.3-13.6) 
0.62 
Aspartate aminotransferase level (n=24) 
 
45 (27-139) NA 
Creatinine level (n=26) 
 
59 (51-72) NA 
*Wilcoxon’s signed rank test for paired data – comparisons between first and second tests, 
NA=comparison not applicable 
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4.4 Change in platelet count according to risk factors 
The mean change in platelet count did not differ by gestational age, level of first platelet 
count, or use of antenatal corticosteroids.  Women who were diagnosed by attending 
clinicians with HELLP syndrome had a mean change in platelet count of 18x10
9
/L, a 
significant difference (p<0.01) when compared with women who did not have HELLP 
syndrome, where the platelet count rose on average by 14.5x10
9
/L.  When the clinical 
diagnosis of HELLP syndrome was ignored and only the AST level was considered, an AST 
level ≥40 U/L was accompanied by a mean decrease of 19.7x109/L, significantly different 
(p<0.01) from women in whom the AST level was normal, where the platelet count increased 
on average by 17.8x10
9
/L (Table 4).  Changes in haemoglobin level were not statistically 
significantly different in women with and without high AST levels (data not shown).  
 
Table 4. Change in platelet counts from first to second testing by the presence of 
absence of possible risk factors. Negative signs indicate a mean reduction in platelet 
count. 
 
Risk factor present: 
Mean difference in platelet count  
P value* Yes No  
Pregnant <34 weeks 2.1±35.5 (n=18) -2.0±38.0 
(n=14)  
0.76 
First platelet count <100x10
9
/L 6.2±15.4 (n=11) -2,8±43.3 
(n=21) 
0.51 
Clinical diagnosis of HELLP syndrome -18.0±27.7 (n=14) 14.5±36.0 
(n=18) 
<0.01 
Aspartate transaminase level ≥40 IU/L -19.7±29.5 (n=12) 17.8±28.8 
(n=12) 
<0.01 
Second platelet count ≥24 hours after 
first 
13.8±48.4 (n=8) -4.2±30.9 
(n=24) 
0.23 
Any betamethasone received 3.6±36.0 (n=18) -4.0±37.1 
(n=14) 
0.56 
*Student’s t-test 
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5. DISCUSSION 
5.1 Main findings 
The three academic hospitals in this study are managed by the South African Government 
and serve low income populations in Johannesburg and surrounding areas.  This prospective 
study provides potentially useful findings regarding women with pre-eclampsia who have 
thrombocytopenia, and may be especially relevant for clinicians who are in the habit of, or 
are forced into, predicting platelet counts in resource limited settings where rapid platelet 
count estimation may not be available.  The high caesarean section rate in this study (97%) 
confirms the clinical need to be aware of platelet count levels in pre-eclamptic women.  
Considerations related to surgical care, such as choice of anaesthesia, choice of abdominal 
incision, and the possible need for platelet transfusion, apply strongly to the care of such 
patients. 
 
The main finding of the study is that prediction of platelet count declines may be dependent 
on the AST level.  A normal level suggests that platelet counts will not decline significantly 
while managing these women in anticipation of delivery.  Conversely, a high AST level (or a 
diagnosis of HELLP syndrome) confers a risk of significant platelet count decline.  To the 
researcher’s knowledge, these findings have not been found in previous studies. 
Interpretation of this finding should perhaps be confined to a raised AST level rather than 
HELLP syndrome, because the diagnosis of HELLP syndrome was only confirmed in one of 
the women with raised AST levels.  There is, however, a tendency in the Wits teaching 
hospitals to speak loosely of HELLP syndrome in any pre-eclamptic a woman who has low 
platelets and a raised AST level.  
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There was no evidence that the initial platelet count on its own, as suggested by some 
studies,
33,55
 could be used to predict the subsequent count.  The study also detected no 
significant effect with administration of steroids, in keeping with the findings for HELLP 
syndrome from the Cochrane systematic review.
58 
 Only the first and second platelet counts 
could be meaningfully analysed, because too few women had a third platelet count 
performed.  Therefore, a trend over a longer period with three or more counts could not be 
discerned. 
 
5.2 Strengths and limitations 
A first strength of this study was its strict inclusion and exclusion criteria, ensuring that even 
with the constraint of late-booking antenatal care, truly pre-eclamptic women were chosen. A 
second strength was the prospective recruitment of participants, with all selection and data 
collection under the control of the researcher, who is a specialist registrar.  Selection bias due 
to misclassification, and information bias due to poor data quality, were therefore minimised.  
It is however possible that some unbooked women presenting with early-onset pre-eclampsia 
were missed.  They had to be excluded because they had no record of a normal antenatal 
blood pressure. 
 
There were several important limitations.  The small sample size, due in part to the stringent 
inclusion criteria, did not allow for much confidence in the sample estimates, nor provide 
much room for subgroup comparisons, nor give information on rate of platelet count 
reductions per unit time.  Nevertheless, the sample size was large enough to detect a 
predictive effect of AST for the platelet count drop.  Another very real reason for the small 
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sample size is that the researcher, as a full-time registrar, was not always able to find the 
necessary time to recruit patients for the study.  While no priority sample size was specified, 
owing to lack of data on platelet count drops, it was hoped that at least 50 patients could be 
recruited.  Related to the small sample size was the inclusion of a large number of women 
with platelet counts ≥100x109/L.  These women only have mild thrombocytopaenia and are 
probably of less clinical interest than those with lower platelet counts, where anaesthetic and 
surgical considerations start to apply.  
 
The finding of the relationship between AST and platelet count drop brought into question 
the incomplete nature of diagnoses of HELLP syndrome in these hospitals.  The study was 
limited by the available data in the files, with most women who had raised AST levels not 
further investigated.  All blood tests used for analysis in this study were done by the on-duty 
clinicians, and the researcher had to be content with the results of whatever tests had been 
requested.  
 
5.3 Implications for practice and research 
The study, while limited, achieved its objectives in tracking platelet counts in pre-eclamptic 
with thrombocytopaenia patients while still pregnant.  There is however, no fine detail in the 
results. Practising clinicians at the three hospitals would be advised to seek urgent platelet 
counts before surgery in pre-eclamptic women who have recent (8-48 hours prior) 
thrombocytopaenia <100x10
9
/L and a raised AST level.  Clinicians can afford to be less 
concerned in patients who have thrombocytopaenia >100x10
9
/L, or have normal AST results. 
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Specific cut off levels cannot be recommended, and clinical acumen with individual patients 
is still required. 
 
Further useful research may focus on women with HELLP syndrome and thrombocytopaenia 
<100x10
9
/L.  A study is needed with adequate power gained from a large enough sample size 
and clear case definition for HELLP syndrome.  Prospective testing at defined intervals 
would be especially useful.  It may then become possible to predict platelet count declines, 
and therefore provide more precise clinical guidelines for urgent repeat platelet count testing 
or, in resource-poor settings, using prediction curves to decide on surgical and anaesthetic 
precautions related to severe thrombocytopaenia.  
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Appendix A: Patient information sheet  
 
 
 
[Name of Principle Investigator] 
 
Information Sheet  
 
Good day, my name is Dr Mama-Asu Koranteng and I am a medical doctor in the obstetrics 
and gynaecology department.  I am doing research as part of my qualification to be a 
specialist in obstetrics and gynaecology.  High blood pressure is a very common problem in 
our hospitals.  I am doing research on high blood pressure in pregnancy and how it affects the 
platelet count.  Platelets are a part of the blood that stops you from bleeding to death if you 
cut your self.  At the moment we do not know what will happen to the platelet count when 
you come into hospital – does it go down, does it go up, or does it stay the same. By 
observing patients such as yourself, we may be able to learn what happens with the platelet 
count.  I am asking for your permission to let me look through your hospital file to see why 
you were admitted, I will then take down your hospital number and check all your blood 
results on the computer until you are discharged.  
 
I am not one of the doctors treating you – I only want to take information about blood 
pressure from your file and follow up the platelet count results. So, what I am doing will not 
affect your treatment at all. Collecting this information is anonymous; your name will not be 
used.  You do not have to decide right now if you are willing to participate.  I can answer any 
questions you may have now or later.  You do not have to take part in this research if you do 
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not wish to do so and refusing to participate will not affect your treatment.  You can change 
your mind about participating at any time.  This information will be shared only with doctors 
and other health care professionals so that we may learn more about high blood pressure in 
pregnancy and the platelets. 
 
Name of Principal Investigator:  Dr Mama- Asu Koranteng  
Cell phone: 0726372648 
Email address makoranteng@gmail.com 
Ethics committee at Wits: (011) 7171234 
Supervisor: Prof E Buchmann 
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Appendix B: 
Informed Consent form for pregnant women with high blood pressure in pregnancy 
(adopted from WHO guidelines) 
 
I have read the information, or it has been read to me. I have had the opportunity to ask 
questions about it and any questions that I have asked have been answered to my satisfaction.   
I consent voluntarily to participate in this research. 
 
Signature of Participant ___________________       Date ___________________________ 
    Or 
Thumb print of participant 
 
 
Signature of witness ______________________            Date ________________________ 
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Appendix C:Data sheet  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital 
CHBH  
CMJAH  
RHM  Study number    
Age   Gravidity  Parity  Gestational 
age booked 
  
   HIV    - +         CD4                      ARVs Y N HIV 
WHO 
staging 
 
Diabetes Y N 
Systolic blood pressure 
at booking (mmHg) 
 Diastolic blood pressure at 
booking (mmHg) 
 Proteinuria at 
booking 
 
Aspirin 
use in 
antenatal 
period 
Y N Aldomet 
use in antenatal 
period 
Y N Nifedipine use in 
antenatal period 
Y N 
Date of 
admission 
 Gestational 
age at 
admission 
 
Highest 
SBP 
(mmHg) 
 Highest DBP 
(mmHg) 
 Quantity of 
proteinuria on 
admission 
 
Peripheral 
smear 
 
Pulmonary 
oedema 
Y N Imminent 
eclampsia 
Y N Symptoms: HELLP 
syndrome 
Y N 
LDH  Haptoglobin  
Dopplers 
(resistance 
index) 
 
 
MgSO4 
administered 
 
 
  Y 
 
 
  N 
 
Steroids 
administered 
none  
Full course not completed by second 
platelet count 
 
Full course completed by second 
platelet count 
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1
st
 result Date Time of 
specimen 
recorded by the 
laboratory 
Recording 
Platelet count    
White cell count 
(WCC) 
   
Haemoglobin 
(Hb) 
   
Haematocrit 
(Hct) 
   
Aspartate 
transaminase 
(AST) 
   
Creatinine    
2
nd
 result Date Time of 
specimen 
recorded by the 
laboratory 
Recording 
Platelet count    
WCC    
Hb    
Hct    
AST    
Creatinine    
3
rd
  result Date Time of 
specimen 
recorded by the 
laboratory 
Recording 
Platelet count    
WCC    
Hb    
Hct    
AST    
Creatinine    
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4
th
  result Date Time of 
specimen 
recorded by the 
laboratory 
Recording 
Platelets    
WCC    
Hb    
Hct    
AST    
Creatinine    
Date of delivery  
Time of delivery  
Mode of delivery  
Birth weight/gestational age  
Outcome (alive/stillbirth)  
Appropriateness for gestational age  
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